Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Short Interest Update

Key Points

• Short interest in Enlivex Therapeutics surged in June, rising 336.3% to 1.51 million shares by June 30. That amounts to about 0.7% of shares sold short, with a days-to-cover ratio of 4.0.
• Analyst sentiment remains mixed, with HC Wainwright maintaining a Buy rating and $300 target, while Wall Street Zen upgraded to Hold and Weiss Ratings reiterated a Sell. The overall consensus rating is Hold with a target price of $247.50.
• The stock fell sharply on the day reported, dropping 7.3% to $6.86 and trading near its 1-year low of $6.42. Institutional ownership remains limited, with hedge funds and other investors holding about 1.02% of the company.

Enlivex Therapeutics Ltd. (NASDAQ:ENLV - Get Free Report) was the recipient of a large growth in short interest during the month of June. As of June 30th, there was short interest totaling 1,511,367 shares, a growth of 336.3% from the June 15th total of 346,372 shares. Approximately 0.7% of the shares of the company are sold short. Based on an average daily trading volume, of 376,254 shares, the days-to-cover ratio is presently 4.0 days.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on ENLV. Wall Street Zen raised Enlivex Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, April 25th. HC Wainwright lifted their target price on shares of Enlivex Therapeutics from $195.00 to $300.00 and gave the company a "buy" rating in a report on Tuesday, April 7th. Finally, Weiss Ratings reiterated a "sell (d)" rating on shares of Enlivex Therapeutics in a research report on Friday, June 26th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $247.50.

Enlivex Therapeutics Trading Down 7.3%

Shares of Enlivex Therapeutics stock traded down $0.54 during trading hours on Friday, hitting $6.86. 96,542 shares of the company were exchanged, compared to its average volume of 27,160. The business has a 50-day moving average of $10.15 and a 200-day moving average of $13.18. Enlivex Therapeutics has a 1 year low of $6.42 and a 1 year high of $31.50. The stock has a market capitalization of $115.52 million, a price-to-earnings ratio of -0.83 and a beta of 1.52.

Hedge Funds Weigh In On Enlivex Therapeutics

A number of large investors have recently bought and sold shares of ENLV. Jane Street Group LLC increased its holdings in shares of Enlivex Therapeutics by 527.4% in the 1st quarter. Jane Street Group LLC now owns 80,759 shares of the company's stock valued at $78,000 after purchasing an additional 67,886 shares in the last quarter. Susquehanna International Group LLP purchased a new stake in Enlivex Therapeutics during the third quarter worth about $57,000. Renaissance Technologies LLC grew its position in Enlivex Therapeutics by 99.4% during the fourth quarter. Renaissance Technologies LLC now owns 313,628 shares of the company's stock worth $221,000 after buying an additional 156,336 shares during the period. HRT Financial LP grew its position in Enlivex Therapeutics by 719.4% during the fourth quarter. HRT Financial LP now owns 153,990 shares of the company's stock worth $108,000 after buying an additional 135,198 shares during the period. Finally, XTX Topco Ltd increased its holdings in Enlivex Therapeutics by 44.8% in the fourth quarter. XTX Topco Ltd now owns 61,800 shares of the company's stock valued at $43,000 after buying an additional 19,132 shares in the last quarter. Hedge funds and other institutional investors own 1.02% of the company's stock.

More Enlivex Therapeutics News

Here are the key news stories impacting Enlivex Therapeutics this week:

• Neutral Sentiment: HC Wainwright reiterated a Buy rating and a $300 price target on Enlivex Therapeutics, while making a series of small upward tweaks to its earnings estimates for FY2026, FY2027 and several quarterly periods. The revisions suggest the analyst remains constructive on the company’s longer-term outlook, but the adjustments were modest and do not appear to be enough on their own to offset recent selling pressure. Article Title
• Negative Sentiment: A separate market note framed ENLV as “Trading Down” and questioned whether it is a sell, which may have reinforced bearish sentiment among traders already focused on the stock’s weak recent trend and volatile volume. Article Title

About Enlivex Therapeutics

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company's lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.